Investment
Features
FeesSafety
Academy
More
Pluang+

TEN Holdings CEO to present live at Skyline Signature Series on Oct 27, sharing company updates and future plans.

Market News
20 Oct 2026
PRNewsWire
View Source
Neutral
TEN Holdings CEO to present live at Skyline Signature Series on Oct 27, sharing company updates and future plans.

TEN Holdings, a technology company specializing in digital experience platforms, announced that CEO Virgilio Torres will deliver a live virtual presentation on October 27 via the Skyline Signature Series. This event provides an opportunity for the company to engage with current and potential investors, sharing updates on its platform TEN, which supports large-scale digital events and plans to expand into AI, automation, and analytics. The presentation will include a live Q&A session, emphasizing TEN Holdings' commitment to transparent communication and growth.

TEN Holdings Inc. participation in the Skyline Signature Series webinar is presented here with Pluang's Technology-sector market data as of Oct 21, 2026 02:31 WIB: Out of 150 priced US tech stocks, 112 rose and 38 fell. Among notable movers, Mondaycom Ltd (MNDY) surged 7.41% to USD 100.34 with a typical hold time of 17 days and 100% sell order activity, contrasting with GoPro Inc (GPRO) which rose 7.21% to USD 1.11 and had a balanced buy/sell order split, and HubSpot Inc (HUBS) which increased 7.00% to USD 251.02 but saw 100% sell orders and a longer hold time of 79 days.

More News

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...

Company Fundamentals
Neutral
31 minutes ago
Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...

Analyst Insights
Bullish
1 hour ago
Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...

Company Fundamentals
Bearish
1 hour ago
CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...

Others
Neutral
1 hour ago
Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App